Dizal registers Phase 2/3 trial pairing birelentinib with R-CHOP in frontline DLBCL
The 880-patient China-based trial puts Dizal's BTK/LYN inhibitor into first-line combination testing against a field of nine direct BTK-targeted comparators.
Executive Summary
- Dizal Pharmaceuticals registered a Phase 2/3 trial testing its BTK and LYN inhibitor birelentinib added to R-CHOP chemoimmunotherapy in patients newly diagnosed with diffuse large B-cell lymphoma who have not received prior anti-lymphoma therapy.
- The trial is registrational and randomized, built as a two-part study: an initial safety-focused stage followed by a larger efficacy comparison measuring progression-free and overall survival against the R-CHOP standard.
- Birelentinib enters a BTK inhibitor field that already includes multiple direct comparators in lymphoma and B-cell malignancies, so the trial's job is to show whether adding a BTK inhibitor to frontline chemoimmunotherapy improves on chemoimmunotherapy alone, not to establish a new mechanism.
- Dizal has completed most of its trials to date, and this is the sponsor's second BTK/LYN inhibitor program to reach clinical registration, following an earlier trial of the same drug class in chronic lymphocytic leukemia.
The trial
The trial, known as TAI-SHAN19 and registered under NCT07712588, will test birelentinib added to R-CHOP, the standard chemoimmunotherapy backbone of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, in adults 18 to 70 with previously untreated diffuse large B-cell lymphoma not otherwise specified. The trial is not yet recruiting, lists China as its country of conduct, and targets 880 patients with a primary completion date of January 2031 and full completion projected for February 2032. NCT07712588Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)NCT07712588
The design
The study is structured in two parts. Part A measures the incidence and severity of adverse events over up to two years, establishing the safety of the combination before the trial advances. Part B measures progression-free survival over up to five years as its efficacy readout, with complete response rate, objective response rate, event-free survival and overall survival tracked as secondary measures. The design is randomized and quadruple-masked, and the trial is marked registrational, meaning its Part B result is intended to support a marketing application rather than serve purely as an exploratory signal. NCT07712588Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)NCT07712588
Competitive position
Birelentinib is not a first-in-class entrant: at least nine direct BTK-targeted comparators are active in overlapping B-cell malignancy settings, including Eli Lilly's pirtobrutinib, BeOne Medicines' sonrotoclax, InnoCare Pharma's orelabrutinib, Guangzhou Lupeng's rocbrutinib, Genmab's epcoritamab, Merck's nemtabrutinib, AstraZeneca's acalabrutinib and BeOne's BGB-16673. AstraZeneca's acalabrutinib is being tested directly in diffuse large B-cell lymphoma in a separate Phase 2 trial (NCT05952024), making it the closest same-indication BTK precedent, though most of the other named comparators are being developed in chronic lymphocytic leukemia or mantle cell lymphoma rather than DLBCL specifically. The stake for TAI-SHAN19 is narrower than establishing a new mechanism: it is whether adding a BTK/LYN inhibitor to R-CHOP produces a progression-free survival benefit over chemoimmunotherapy alone in the frontline setting, a combination-with-standard-of-care question rather than a monotherapy efficacy question.
Sponsor context
Dizal Pharmaceuticals has completed 18 of 19 prior trials, with one termination, across a 40-trial pipeline that includes 15 currently recruiting and four active but not recruiting. Birelentinib itself already has one other registered trial in chronic lymphocytic leukemia (NCT07139873), also sponsored by Dizal, indicating the DLBCL study is the drug's second indication in clinical testing. Neither an FDA approval history nor a DailyMed label was found for birelentinib, consistent with a drug still in trial-stage development.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.